SAB Biotherapeutics to Present New Data at ISIRV OPTIONS XI Conference on SAB-176 Phase 2a Influenza Trial and SAB-185’s Effectiveness Against Multiple COVID-19 Variants
September 23, 2022 08:30 ET
|
SAB Biotherapeutics, Inc.
SIOUX FALLS, S.D., Sept. 23, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), ("SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces...
SAB Biotherapeutics Provides Company Update for Q2 2022 Financial Results
August 10, 2022 08:15 ET
|
SAB Biotherapeutics, Inc.
SIOUX FALLS, S.D., Aug. 10, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces...
SAB Biotherapeutics Advancing Pipeline and Expands into Treatment for C. Diff. as DoD Contract Winds Down
August 09, 2022 16:30 ET
|
SAB Biotherapeutics, Inc.
SIOUX FALLS, S.D., Aug. 09, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces...
SAB Biotherapeutics to Host Virtual 2022 Annual R&D Portfolio Update
August 04, 2022 08:30 ET
|
SAB Biotherapeutics, Inc.
SIOUX FALLS, S.D., Aug. 04, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (NASDAQ: SABS), a clinical-stage biopharmaceutical company with a first of its kind immunotherapy platform that produces...
SAB Biotherapeutics Announces Election of Rear Admiral (retired) Scott Giberson, RPh, MPH, D.Sc., to Board of Directors
July 11, 2022 08:00 ET
|
SAB Biotherapeutics, Inc.
SIOUX FALLS, S.D., July 11, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces...
SAB Biotherapeutics Hosts U.S. Representatives Dusty Johnson and Dean Phillips for South Dakota Facility Tour
July 05, 2022 08:00 ET
|
SAB Biotherapeutics, Inc.
SIOUX FALLS, S.D., July 05, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB, or “the Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that...
SAB Biotherapeutics Announces Appointment of Alexandra Kropotova, M.D., as Chief Medical Officer
June 06, 2022 08:30 ET
|
SAB Biotherapeutics, Inc.
SIOUX FALLS, S.D., June 06, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces...
SAB Biotherapeutics Chief Operating Officer, Dr. Christoph Bausch, to Present at the Large Animal Genetic Engineering Summit
May 31, 2022 08:30 ET
|
SAB Biotherapeutics, Inc.
In-person presentation titled ‘Leveraging Genetically Engineered Ungulates to Produce Novel Human Biotherapeutics’ to take place on June 7 in Park City, Utah Dr. Christoph Bausch to share early...
SAB Biotherapeutics Provides Company Update for Q1 2022 Financial Results
May 12, 2022 16:15 ET
|
SAB Biotherapeutics, Inc.
Full data from Phase 2a trial that evaluated SAB-176 for treatment of seasonal influenza expected third quarter 2022 – first clinical data set from novel platform Phase 2 data for SAB-185 expected to...
SAB Biotherapeutics to Present at 2022 H.C. Wainwright Global Investment Conference
May 12, 2022 09:42 ET
|
SAB Biotherapeutics, Inc.
SIOUX FALLS, S.D., May 12, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (NASDAQ: SABS), announced today its participation at the H.C. Wainwright Global Investment Conference, which takes place May...